Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate–resistant prostate cancer
S Ramalingam, MS Humeniuk, R Hu… - … Oncology: Seminars and …, 2017 - Elsevier
Purpose Evidence suggests differences in androgen receptor AR signaling between black
(B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA)
for patients with metastatic castration–resistant prostate cancer (mCRPC) enrolled few black
patients, a population with a higher mortality from prostate cancer. Our primary objective was
to determine differences in response to AA between B and W patients. Methods We
performed a retrospective case-control study of B vs. W patients treated with AA between …
(B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA)
for patients with metastatic castration–resistant prostate cancer (mCRPC) enrolled few black
patients, a population with a higher mortality from prostate cancer. Our primary objective was
to determine differences in response to AA between B and W patients. Methods We
performed a retrospective case-control study of B vs. W patients treated with AA between …